CAJ | 학술논문

目的：探讨培美曲塞联合EGFR-TKI治疗EGFR-TKI治疗失败后的晚期非小细胞肺癌的疗效和安全性。方法对EGFR-TKI治疗失败后的晚期NSCLC患者给予培美曲塞（500 mg/m2，静脉滴注，d1，每21天重复1次）联合原EGFR-TKI治疗，EGFR-TKI剂量不变。结果全组7例患者中6例可进行疗效评价，PR 2例，SD 2例，PD 2例，有效率为33．3％，疾病控制率66．7％。7例患者PFS 0．6～11个月，中位PFS 2．5个月。1例在培美曲塞联合EGFR-TKI后出现皮疹加重（2度），1例患者出现粒细胞减少，1例患者出现转氨酶升高，1例出现4度粒细胞减少及3度血小板减低，并出现2度粒缺性发热。结论晚期NSCLC患者在EGFR-TKI治疗失败后采用培美曲塞联合EGFR-TKI治疗，疗效显著，不良反应轻微且易控制。
목적：탐토배미곡새연합EGFR-TKI치료EGFR-TKI치료실패후적만기비소세포폐암적료효화안전성。방법대EGFR-TKI치료실패후적만기NSCLC환자급여배미곡새（500 mg/m2，정맥적주，d1，매21천중복1차）연합원EGFR-TKI치료，EGFR-TKI제량불변。결과전조7례환자중6례가진행료효평개，PR 2례，SD 2례，PD 2례，유효솔위33．3％，질병공제솔66．7％。7례환자PFS 0．6～11개월，중위PFS 2．5개월。1례재배미곡새연합EGFR-TKI후출현피진가중（2도），1례환자출현립세포감소，1례환자출현전안매승고，1례출현4도립세포감소급3도혈소판감저，병출현2도립결성발열。결론만기NSCLC환자재EGFR-TKI치료실패후채용배미곡새연합EGFR-TKI치료，료효현저，불량반응경미차역공제。
Objective To study the efficacy and safety of pemetrexed combined with EGFR-TKI for advanced non-small-cell lung cancer(NSCLC) patients who failed EGFR-TKI.Methods Advanced NSCLC patients who failed EGFR-TKI,received pemetrexed(500 mg/m2 ,Ivggt,d1,3 weeks as 1 cycle) combined with EGFR-TKI.Rusults 6 patients got evaluation in 7 en-rolled patients,there were 2 PR,2 SD and 2 PD.RR(response rate) was 33.3% and DCR(disease control rate) was 66.7%. PFS(progression-free survival) of 7 patients was 0.6~11 months,and median PFS was 2.5 months.There were 1 case of in-creased rash(grade 2),1 case of granulocytopenia(grade 1);1 case of alanine aminotransferase(grade 1),1case of grade 4 gran-ulocytopenia and 1 case of grade 3 thrombocytopenia and grade 2 fever.Conclusion Pemetrexed combined with EGFR-TKI is ef-fective for NSCLC patients who failed EGFR-TKI treatment,with mild and tolerable adverse events .